Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain.
-
Elena Roel
- Andrea Pistillo
-
Martina Recalde
-
Anthony G. Sena
- Sergio Fernández-Bertolín
- María Aragón
- Diana Puente
-
Waheed-Ul-Rahman Ahmed
-
Heba Alghoul
-
Osaid Alser
-
Thamir M. Alshammari
-
Carlos Areia
-
Clair Blacketer
- William Carter
-
Paula Casajust
- Aedin C. Culhane
-
Dalia Dawoud
-
Frank DeFalco
-
Scott L. Duvall
-
Thomas Falconer
- Asieh Golozar
-
Mengchun Gong
- Laura Hester
-
George Hripcsak
- Eng Hooi Tan
- Hokyun Jeon
- Jitendra Jonnagaddala
-
Lana Y.H. Lai
- Kristine E. Lynch
- Michael E. Matheny
- Daniel R. Morales
- Karthik Natarajan
-
Fredrik Nyberg
-
Anna Ostropolets
- José D. Posada
-
Albert Prats-Uribe
-
Christian G. Reich
- Donna Rivera
- Lisa M. Schilling
- Isabelle Soerjomataram
- Karishma Shah
- Nigam Shah
- Yang Shen
- Matthew Spotniz
- Vignesh Subbian
-
Marc A. Suchard
- Annalisa Trama
-
Lin Zhang
- Ying Zhang
- Patrick Ryan
-
Daniel Prieto-Alhambra
-
Kristin Kostka
-
Talita Duarte-Salles
Description
Purpose We aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.
Methods We conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: i) diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.
Results We included 118,155 patients with a cancer history in the COVID-19 diagnosed and 41,939 in the COVID-19 hospitalized cohorts. The most frequent cancer subtypes were prostate and breast cancer (range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events.
Conclusion Patients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.
Files
Roel - 2021 - Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain.pdf
Files
(1.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:dbb61dfe97e05b652d9c4fe258ce613f
|
1.2 MB | Preview Download |